Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have earned an average rating of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $36.90.

A number of analysts recently issued reports on the company. The Goldman Sachs Group raised their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Citigroup lifted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. UBS Group started coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. Finally, Stifel Nicolaus boosted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $13.22 on Friday. The firm has a 50 day simple moving average of $16.25 and a 200-day simple moving average of $18.87. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -3.64 and a beta of 0.86. Syndax Pharmaceuticals has a 1-year low of $12.40 and a 1-year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the previous year, the company posted ($0.73) earnings per share. Equities analysts expect that Syndax Pharmaceuticals will post -2.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SNDX. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $27,000. Values First Advisors Inc. purchased a new position in shares of Syndax Pharmaceuticals in the 3rd quarter valued at about $30,000. nVerses Capital LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Inspire Investing LLC lifted its stake in Syndax Pharmaceuticals by 15.0% during the second quarter. Inspire Investing LLC now owns 17,290 shares of the company’s stock worth $355,000 after purchasing an additional 2,258 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).